Fulgent Genetics, Inc.
FLGT • NASDAQ
Fulgent Genetics, Inc. is a medical - diagnostics & research company in the healthcare sector trading on NASDAQ, led by CEO Ming Hsieh, with a market cap of $486.9M.
CEOMing Hsieh
Next Earnings
Upcoming earnings announcement for Fulgent Genetics, Inc.
Date
Friday, May 1, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.48
Revenue Estimate
$68.6M
Earnings History
Past 12 earnings reports for Fulgent Genetics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 27, 2026 | Q4 2025 | $0.16Est: -$0.09 | +277.8% | $83.3MEst: $85.4M | -2.4% |  10-K |
| Nov 7, 2025 | Q3 2025 | $0.14Est: -$0.36 | +138.9% | $84.1MEst: $81.4M | +3.3% | 10-Q |
| Aug 1, 2025 | Q2 2025 | $0.07Est: -$0.33 | +121.2% | $81.8MEst: $76.1M | +7.5% | 10-Q |
| May 2, 2025 | Q1 2025 | $0.04Est: -$0.18 | +122.2% | $73.5MEst: $71.3M | +3.1% | 10-Q |
| Feb 28, 2025 | Q4 2024 | $0.04Est: -$0.12 | +133.3% | $76.2MEst: $74.8M | +1.9% | 10-K |
| Nov 8, 2024 | Q3 2024 | $0.31Est: -$0.15 | +306.7% | $71.7MEst: $71.7M | +0.0% | 10-Q |
| Aug 2, 2024 | Q2 2024 | $0.15Est: -$0.30 | +150.0% | $71.0MEst: $69.1M | +2.8% | 10-Q |
| May 3, 2024 | Q1 2024 | -$0.01Est: -$0.32 | +96.9% | $64.5MEst: $65.4M | -1.3% | 10-Q |
| Feb 28, 2024 | Q4 2023 | $0.28Est: -$0.29 | +196.6% | $70.5MEst: $66.3M | +6.3% | 10-K |
| Nov 3, 2023 | Q3 2023 | -$0.39Est: -$0.33 | -18.2% | $84.7MEst: $63.4M | +33.6% | — |
| Aug 4, 2023 | Q2 2023 | -$0.08Est: -$0.33 | +75.8% | $67.9MEst: $62.7M | +8.3% | 10-Q |
| May 5, 2023 | Q1 2023 | -$0.22Est: -$0.43 | +48.8% | $66.2MEst: $60.1M | +10.2% | — |